5月27日，科伦博泰生物盘中上涨3.07%，报477.0港元，成交额1.26亿港元。
消息面上，野村近日上调公司目标价至544.42港元并维持"买入"评级，认为其TROP2 ADC药物sac-TMT联合帕博利珠单抗一线治疗PD-L1阳性非小细胞肺癌的III期临床数据令人鼓舞，PFS风险比达0.35，OS亦呈积极趋势（HR=0.55），系全球首个在该适应症III期中显示PFS改善的ADC药物。此外，公司多项注册研究入选ASCO年会口头报告专场，管线全球价值兑现预期持续催化股价表现。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.